Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

NCT00318448 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
201
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi